Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22046Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Laffi, G. | en |
| dc.contributor.author | Daskalopoulos, G. | en |
| dc.contributor.author | Kronborg, I. | en |
| dc.contributor.author | Hsueh, W. | en |
| dc.contributor.author | Gentilini, P. | en |
| dc.contributor.author | Zipser, R. D. | en |
| dc.date.accessioned | 2015-11-24T19:20:31Z | - |
| dc.date.available | 2015-11-24T19:20:31Z | - |
| dc.identifier.issn | 0016-5085 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22046 | - |
| dc.rights | Default Licence | - |
| dc.subject | 6-Ketoprostaglandin F1 alpha/urine | en |
| dc.subject | Adult | en |
| dc.subject | Cyclooxygenase Inhibitors | en |
| dc.subject | Dinoprostone | en |
| dc.subject | Humans | en |
| dc.subject | Ibuprofen/*therapeutic use/toxicity | en |
| dc.subject | Indenes/*therapeutic use | en |
| dc.subject | Kidney/*drug effects/metabolism | en |
| dc.subject | Kidney Function Tests | en |
| dc.subject | Liver Cirrhosis, Alcoholic/*drug therapy | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prostaglandins E/urine | en |
| dc.subject | Renal Circulation/drug effects | en |
| dc.subject | Sulindac/*therapeutic use/toxicity | en |
| dc.subject | Thromboxane B2/metabolism | en |
| dc.subject | Time Factors | en |
| dc.title | Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/3079594 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1986 | - |
| heal.abstract | Nonsteroidal antiinflammatory drugs impair renal function in susceptible patients with cirrhosis and ascites. A new antiinflammatory drug, sulindac, is reported not to affect renal function. To evaluate its renal-sparing mechanism, sulindac was administered for 5 days and ibuprofen for 1 day to 10 patients and paraaminohippurate and inulin clearances, serum and urine eicosanoids, and serum and urine sulindac metabolites were monitored. Ibuprofen reduced renal clearances in the 5 subjects with greatest sodium retention, whereas sulindac had no effect. Plasma concentration of the active sulfide metabolite was markedly increased in liver patients, and this concentration correlated with the inhibition of serum thromboxane (r = 0.75, p = 0.01). The percent inhibition of serum thromboxane with sulindac administration correlated with the inhibition of urinary eicosanoids (r = 0.68-0.81, all p less than 0.02). Ibuprofen was generally a more potent inhibitor of serum and urine eicosanoids. Thus, a major factor in the renal-sparing effect of sulindac appears to be its less potent inhibition of renal and extrarenal cyclooxygenase systems. | en |
| heal.journalName | Gastroenterology | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
